Catalent to acquire Canada-based Accucaps; terms not disclosed
Catalent announced it has agreed to acquire Accucaps Industries, a Canada-based developer and manufacturer of Over-the-Counter, high potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed. The acquisition, which is subject to Canadian governmental approval, will complement Catalent's global OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging, strengthening Catalent's ability to offer customers turnkey solutions. Upon completion of the acquisition, Accucaps' over 500 employees, at its two facilities in Windsor and Strathroy, Ontario, will join Catalent's global network of 11 Softgel Technologies facilities. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent's. Catalent was advised by RBC Capital Markets.